Table 3. Genomics-driven therapeutics.
| Clinical trial | ||
|---|---|---|
| Number of patients eligible | 15 | |
| Number of possible trial per patient (median, range) | 1 (1-4) | |
| Number of patients actually enrolled | 3 | |
| Targets | Targeted therapy | Best Response |
| PTEN deletion | AKT/S6 inhibitor | Not available* |
| PIK3CA mutation | AKT/S6 inhibitor | Stable disease (≤4 months)** |
| FGFR2 amplification | FGFR inhibiton | Stable disease (≤ 4 months) |
| “off-label” treatment proposal | ||
|---|---|---|
| Number of patients eligible | 21 | |
| Number of possible marketed therapy (median, range) | 1 (1-3) | |
| Number of patients treated | 8 | |
| Targets | Targeted therapy | Best Response |
| BRCA2 mut | carboplatin | Partial response |
| PIK3CA mut | everolimus | Stable disease (> 6 months) |
| PIK3CA mut | everolimus | Not available* |
| PIK3CA mut | everolimus | Progressive disease** |
| PIK3CA mut -PTENdel | everolimus | Progressive disease |
| ESR1 mutation | fulvestrant | Progressive disease*** |
| ESR1 mutation | fulvestrant | Progressive disease |
| JAK2 amplification | ruxolitinib | Progressive disease |
*
Early treatment discontinuation due to toxicity
**
This same patient was treated in both cohorts
***
This patient had dissociated response, with some lesions improved while other progressed